Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Jun 20, 2019 - Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Jun 18, 2019 - Pfizer could be only the first of several to spend billions buying smaller biotech.
Jun 17, 2019 - AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Jun 14, 2019 - GILD vs. ILMN: Which Stock Is the Better Value Option?
Jun 12, 2019 - CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Jun 05, 2019 - Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2019 Global Healthcare Brokers Conference June 5, 2019 11:30 am ET Corporate Participants Daniel O’Day - Chairman and Chief Executive Officer Conference C
Jun 04, 2019 - here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
Jun 03, 2019 - Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.